Introduction: Activation of VEGFR2 and MET is implicated in driving growth of NET. Cabozantinib inhibits VEGFR2, MET, AXL, RET.
Aim(s): We conducted a two-cohort phase II study to evaluate efficacy of cabozantinib in patients (pts) with advanced carcinoid (CARC) or pancreatic NET (pNET) (NCT01466036).
Materials and methods: Pts with progressive, well-differentiated CARC or pNET were treated with cabozantinib 60 mg daily. Pts were restaged q2 cycles for the first 6 cycles, then q3 cycles. The primary endpoint was response rate (RECIST 1.1).
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Jennifer Chan
, Faris J
, Murphy J
, Blaszkowsky L
, McCleary N
, Meyerhardt J
, Abrams T
, Zhang S
, Reardon A
, Fitzpatrick B
, Kulke M
, Ryan D
To read results and conclusion, please login ...
Further abstracts you may be interested in